Valence ロゴ
人気
ログイン
Loading data for IFRX — first visit, this takes a few seconds.

ウォッチリストに追加

InflaRx N.V.

NasdaqGS: IFRX · リアルタイム株価 · USD
2.10
+0.08 (3.96%)
終値時点： Aug 21, 2026, 8:00 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

InflaRx N.V.（IFRX）の株価・分析・データ

3.96%

データがありません

買気配1.53
時価総額309.47M
売上高（TTM）-10.1K
純利益（TTM）-39.14M
2.52
-0.58
n/a
-5.2
PBR（TTM）1.83
PSR（TTM）-30637.88
決算発表日Nov 9, 2026
売気配2.59
出来高419,898
平均出来高（20日）1,120,791
始値2.03
前日終値2.02
当日レンジ2.02 - 2.12
52週レンジ0.80 - 2.95
アナリストn/a
目標株価n/a
配当n/a
権利落ち日n/a

IFRXについて

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering f...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Nov 7, 2017
従業員数 65
上場取引所 NasdaqGS
ティッカー IFRX
ウェブサイト https://www.inflarx.de
企業情報の全文

業績

2025年のInflaRxの売上高は29.33Kで、前年の165.79Kから-82.31%の減少でした。 利益は-45.63Mで、-0.93%の減少でした。

財務諸表

決算サプライズ

InflaRxはAug 6, 2026に四半期決算を発表しました：
  • 売上高は $0 で、予想を下回りました $0, うち -100.00% の前年比減少.
  • EPSは -0.09 で、予想を下回りました -0.04, うち 57.14% の前年比増加にあたります.

次回決算発表

InflaRx N.V.の決算発表予定日は Nov 9, 2026, 寄り付き前の予定です。
アナリストの売上高予想は ... アップグレード
news image

3週間前 · Zacks

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara (CERT) delivered earnings and revenue surprises of -20.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

news image

2か月前 · Zacks

Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?

Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near t...

news image

2か月前 · Insider Monkey

What Do Analysts Say About InflaRx N.V. (IFRX)?

While InflaRx N.V. (NASDAQ:IFRX) has gained 82.18% year-to-date, analysts continue to see 385.90% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. That analyst convi...

news image

2か月前 · Insider Monkey

Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now

InflaRx N.V. (NASDAQ:IFRX) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 13, 2026, Raymond James upgraded InflaRx N.V. (NASDAQ:IFRX) to Strong Buy from Outperform with a price target ...

news image

3か月前 · MarketBeat

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company ...

2ページ中1ページ